<?xml version="1.0" encoding="UTF-8"?>
<p>Influenza A virus is the most common type among the viruses that cause influenza epidemics, and influenza A viruses can be divided into various subtypes based on the hemagglutinin and neuraminidase proteins on the viral surface (
 <xref rid="B1" ref-type="bibr">1</xref>). H5N1 is a highly pathogenic avian influenza virus subtype that can cause severe acute lung injury (ALI) in human subjects (
 <xref rid="B2" ref-type="bibr">2</xref>). Infection with H5N1 virus is associated with a 52.79% mortality rate (
 <ext-link ext-link-type="uri" xlink:href="https://www.who.int/influenza/human_animal_interface/2019_02_12_tableH5N1.pdf?ua=1" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.who.int/influenza/human_animal_interface/2019_02_12_tableH5N1.pdf?ua=1</ext-link>). However, effective treatments are limited. The use of corticoids is controversial, and extracorporeal membrane oxygenation (ECMO), artificial liver support system (ALSS), and mechanical ventilation are often expensive (
 <xref rid="B3" ref-type="bibr">3</xref>). Thus, there is an urgent and continuous need for novel treatments.
</p>
